Gilead Sciences (GILD) : Blair William Coil scooped up 66,039 additional shares in Gilead Sciences during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 8, 2016. The investment management firm now holds a total of 2,370,178 shares of Gilead Sciences which is valued at $188,595,063.Gilead Sciences makes up approximately 1.66% of Blair William Coil’s portfolio.
Other Hedge Funds, Including , Silicon Valley Capital Partners reduced its stake in GILD by selling 206 shares or 1.18% in the most recent quarter. The Hedge Fund company now holds 17,204 shares of GILD which is valued at $1,368,922. Gilead Sciences makes up approx 1.00% of Silicon Valley Capital Partners’s portfolio.Exane Derivatives boosted its stake in GILD in the latest quarter, The investment management firm added 375 additional shares and now holds a total of 17,645 shares of Gilead Sciences which is valued at $1,413,188. Gilead Sciences makes up approx 0.23% of Exane Derivatives’s portfolio.Davy Asset Management Ltd reduced its stake in GILD by selling 9,733 shares or 17.41% in the most recent quarter. The Hedge Fund company now holds 46,177 shares of GILD which is valued at $3,698,316. Gilead Sciences makes up approx 0.74% of Davy Asset Management Ltd’s portfolio.Redwood Investments reduced its stake in GILD by selling 166,643 shares or 99.99% in the most recent quarter. The Hedge Fund company now holds 10 shares of GILD which is valued at $818.Pitcairn Co reduced its stake in GILD by selling 103 shares or 0.82% in the most recent quarter. The Hedge Fund company now holds 12,479 shares of GILD which is valued at $1,020,657. Gilead Sciences makes up approx 0.13% of Pitcairn Co’s portfolio.
Gilead Sciences closed down -0.01 points or -0.01% at $79.65 with 74,64,775 shares getting traded on Monday. Post opening the session at $79.88, the shares hit an intraday low of $79.43 and an intraday high of $80.09 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Gilead Sciences reported $3.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Jul 25, 2016. Analyst had a consensus of $3.01. The company had revenue of $7776.00 million for the quarter, compared to analysts expectations of $7795.08 million. The company’s revenue was down -5.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $3.15 EPS.
Investors should note that on Jul 25, 2016, Gilead Sciences announced a cash dividend of $0.4700. The company’s management has announced Sep 14, 2016 as the ex-dividend date and fixed the record date on Sep 16, 2016. The payable date has been fixed on Sep 29, 2016.
Many Wall Street Analysts have commented on Gilead Sciences. Gilead Sciences was Downgraded by Argus to ” Hold” on Jul 29, 2016. Shares were Reiterated by RBC Capital Mkts on Jul 26, 2016 to “Outperform” and Lowered the Price Target to $ 105 from a previous price target of $120 .Gilead Sciences was Downgraded by Needham to ” Hold” on Jul 26, 2016.
Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.